Irish clinical research provider Icon said today its said first-quarter profit increased 37 per cent as more drugmakers used its services.
Net income rose to $16.9 million, or 56 cents a share, from $12.3 million, or 42 cents, a year earlier, the Dublin-based company said today in a Business Wire statement. Icon forecast full-year revenue of $840 million to $860 million and earnings per share of $2.35 to $2.45.
Icon, which tests new medicines for pharmaceutical and biotechnology companies, added medical workers in Europe with the acquisition of DOCS International in July to meet increased demand for drug trials.
Bloomberg